Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 18/20 | 0.56 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.52 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL663351 | 0.95 | CHRM3 (0.56) | CHRM3ADRB2CHRM5CHRM1 | |
| SCHEMBL661698 | 0.90 | CHRM3 (0.55) | CHRM3ADRB2CHRM5CHRM1 | |
| SCHEMBL663130 | 0.89 | CHRM3 (0.57) | CHRM3ADRB2 | |
| SCHEMBL663576 | 0.89 | CHRM3 (0.57) | CHRM3CHRM1 | |
| SCHEMBL662514 | 0.89 | CHRM3 (0.56) | CHRM3ADRB2 | |
| SCHEMBL662193 | 0.88 | CHRM3 (0.60) | CHRM3 | |
| SCHEMBL663342 | 0.88 | CHRM3 (0.49) | CHRM3ADRB2LTB4RCHRM5CHRM1 | |
| Iodide SCHEMBL100421 | 0.88 | LTB4R (0.48) | CHRM3ADRB2LTB4RSMN1; SMN2 | |
| SCHEMBL661329 | 0.88 | CHRM3 (0.51) | CHRM3ADRB2 | |
| SCHEMBL661552 | 0.87 | CHRM3 (0.53) | CHRM3ADRB2CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | TEIJIN PHARMA LIMITED (JP) | 2012-02-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | ADRB2, AGTR2, ADRB3 | CHRM3 9/4885ADRB2 1/4885LTB4R 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.